X4 Pharmaceuticals, Inc (XFOR) Interest Expense USD 2017 - 2024

Historical data

Taxonomy & unit: us-gaap: USD
Description: Amount of the cost of borrowed funds accounted for as interest expense.
Summary: X4 Pharmaceuticals, Inc quarterly/annual Interest Expense history and growth rate from 2017 to 2024.
X4 Pharmaceuticals, Inc Interest Expense for the quarter ending March 31, 2024 was $1.87 M, a 69% increase year-over-year.
X4 Pharmaceuticals, Inc Interest Expense for the twelve months ending March 31, 2024 was $6.54 M, a 56.2% increase year-over-year.
X4 Pharmaceuticals, Inc annual Interest Expense for 2023 was $5.78 M, a 44.7% increase from 2022.
X4 Pharmaceuticals, Inc annual Interest Expense for 2022 was $3.99 M, a 9.64% increase from 2021.
X4 Pharmaceuticals, Inc annual Interest Expense for 2021 was $3.64 M, a 35.5% increase from 2020.

Interest Expense, Trailing 12 Months (USD)

Interest Expense, Quarterly (USD)

Interest Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q1 2024	$6.54 M	$1.87 M	+$765 K	+69%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	$5.78 M	$1.89 M	+$742 K	+64.9%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-21
Q3 2023	$5.04 M	$1.63 M	+$616 K	+60.5%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-09
Q2 2023	$4.42 M	$1.15 M	+$230 K	+25.1%	Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-10
Q1 2023	$4.19 M	$1.11 M	+$196 K	+21.5%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	$3.99 M	$1.14 M	+$218 K	+23.5%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-21
Q3 2022	$3.78 M	$1.02 M	+$98 K	+10.7%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-09
Q2 2022	$3.68 M	$918 K	+$13 K	+1.44%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-10
Q1 2022	$3.66 M	$913 K	+$22 K	+2.47%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	$3.64 M	$926 K	+$206 K	+28.6%	Oct 1, 2021	Dec 31, 2021	10-K	2024-03-21
Q3 2021	$3.44 M	$920 K	+$223 K	+32%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	$3.21 M	$905 K	+$218 K	+31.7%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	$3 M	$891 K	+$307 K	+52.6%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-12
Q4 2020	$2.69 M	$720 K	+$172 K	+31.4%	Oct 1, 2020	Dec 31, 2020	10-K	2023-03-21
Q3 2020	$2.52 M	$697 K	+$9 K	+1.31%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	$2.51 M	$687 K	+$175 K	+34.2%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-03
Q1 2020	$2.33 M	$584 K	+$185 K	+46.4%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	$2.15 M	$548 K	+$312 K	+132%	Oct 1, 2019	Dec 31, 2019	10-K	2022-03-17
Q3 2019	$1.84 M	$688 K	+$540 K	+365%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019	$1.3 M	$512 K	+$345 K	+207%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-04
Q1 2019	$950 K	$399 K	+$230 K	+136%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-07
Q4 2018	$720 K	$236 K	+$1.55 M		Oct 1, 2018	Dec 31, 2018	10-K	2021-03-19
Q3 2018	-$832 K	$148 K	-$195 K	-56.9%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-07
Q2 2018	-$637 K	$167 K	-$277 K	-62.4%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-07
Q1 2018	-$360 K	$169 K	-$850 K	-83.4%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-15
Q4 2017	$490 K	-$1.32 M			Oct 1, 2017	Dec 31, 2017	10-K	2020-03-12
Q3 2017		$343 K			Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-09
Q2 2017		$444 K			Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-13
Q1 2017		$1.02 M			Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.